Juanita Diaz-Romero

Mexico City, DIF, Mexico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

Response to the Letter to the Editor Entitled "Diagnostic Latency and Unmeasured Disease Severity In Male Lupus Nephritis".

Response to the Letter to the Editor Entitled "Diagnostic Latency and Unmeasured Disease Severity In Male Lupus Nephritis".

Journal: Kidney international reports

Published: March 01, 2026

A Pooled Analysis of Sex Differences in Lupus Nephritis.

A Pooled Analysis of Sex Differences in Lupus Nephritis.

Journal: Kidney international reports

Published: September 06, 2025

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study.

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: August 07, 2025

Bias due to interval censored outcomes in a study of flare risk after hydroxychloroquine taper/cessation in systemic lupus erythematosus.

Bias due to interval censored outcomes in a study of flare risk after hydroxychloroquine taper/cessation in systemic lupus erythematosus.

Journal: Journal of clinical epidemiology

Published: June 20, 2025

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring.

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: May 22, 2025

Antimitochondrial antibodies in systemic lupus erythematosus are associated with and predict nephritis, arterial vascular events, and mortality.

Antimitochondrial antibodies in systemic lupus erythematosus are associated with and predict nephritis, arterial vascular events, and mortality.

Journal: Annals of the rheumatic diseases

Published: May 06, 2025

Two-year treatment experience with BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: An exploratory, phase II maintenance trial.

Two-year treatment experience with BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: An exploratory, phase II maintenance trial.

Journal: Lupus

Published: March 19, 2025

Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary.

Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary.

Journal: Immunotherapy

Published: February 25, 2025

Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary.

Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary.

Journal: Immunotherapy

Published: February 25, 2025

Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set.

Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set.

Journal: Seminars in arthritis and rheumatism

Published: November 07, 2024

Coronary Artery Calcification Progression in Patients With Systemic Lupus Erythematosus.

Coronary Artery Calcification Progression in Patients With Systemic Lupus Erythematosus.

Journal: The Journal of rheumatology

Published: June 14, 2024

OMERACT systemic lupus erythematosus domain survey.

OMERACT systemic lupus erythematosus domain survey.

Journal: Seminars in arthritis and rheumatism

Published: March 14, 2024

Showing 1-12 of 100

Last Updated: 09/26/2026